Unity Biotechnology’s $85 Million Initial Public Offering


Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 5,000,000 shares of common stock of Unity Biotechnology, Inc.

Goldman Sachs & Co. LLC, Morgan Stanley, Citigroup and Mizuho Securities acted as underwriters on the offering.

Unity Biotechnology’s common stock is listed on the NASDAQ Global Select Market under the symbol “UBX.”

Unity Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. Unity Biotechnology’s initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions, such as osteoarthritis, eye diseases and pulmonary diseases.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Marcus K. Hintze and Xin (Anita) Guo. Partner Rachel D. Kleinberg and associate Andrew Imber provided tax advice. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Marcus Hintze – Davis Polk & Wardwell; Xin Guo – Davis Polk & Wardwell; Andrew Imber – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Citigroup Inc.; Goldman, Sachs & Co.; Morgan Stanley; Mizuho Securities;